Cargando…

Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus

BACKGROUND: We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM). METHODS: We conducted a ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantovani, Alessandro, Morieri, Mario Luca, Palmisano, Luisa, Masulli, Maria, Cossu, Efisio, Baroni, Marco Giorgio, Bonomo, Katia, Cimini, Flavia Agata, Cavallo, Gisella, Buzzetti, Raffaella, Mignogna, Carmen, Leonetti, Frida, Bacci, Simonetta, Trevisan, Roberto, Pollis, Riccardo Maria, Aldigeri, Raffaella, Cas, Alessandra Dei, de Kreutzenberg, Saula Vigili, Targher, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416459/
https://www.ncbi.nlm.nih.gov/pubmed/37563618
http://dx.doi.org/10.1186/s12933-023-01945-x
_version_ 1785087782169870336
author Mantovani, Alessandro
Morieri, Mario Luca
Palmisano, Luisa
Masulli, Maria
Cossu, Efisio
Baroni, Marco Giorgio
Bonomo, Katia
Cimini, Flavia Agata
Cavallo, Gisella
Buzzetti, Raffaella
Mignogna, Carmen
Leonetti, Frida
Bacci, Simonetta
Trevisan, Roberto
Pollis, Riccardo Maria
Aldigeri, Raffaella
Cas, Alessandra Dei
de Kreutzenberg, Saula Vigili
Targher, Giovanni
author_facet Mantovani, Alessandro
Morieri, Mario Luca
Palmisano, Luisa
Masulli, Maria
Cossu, Efisio
Baroni, Marco Giorgio
Bonomo, Katia
Cimini, Flavia Agata
Cavallo, Gisella
Buzzetti, Raffaella
Mignogna, Carmen
Leonetti, Frida
Bacci, Simonetta
Trevisan, Roberto
Pollis, Riccardo Maria
Aldigeri, Raffaella
Cas, Alessandra Dei
de Kreutzenberg, Saula Vigili
Targher, Giovanni
author_sort Mantovani, Alessandro
collection PubMed
description BACKGROUND: We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM). METHODS: We conducted a retrospective, multicenter, cross-sectional study involving 1,254 adults with established T1DM without pre-existing CVD. We used the hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting hepatic steatosis (defined as HSI > 36), with or without coexisting significant fibrosis (defined as FIB-4 index ≥ 1.3 or < 1.3). We calculated the Steno type 1 risk engine and the atherosclerotic CVD (ASCVD) risk score to estimate the 10-year risk of developing a first fatal or nonfatal CVD event. RESULTS: Using the Steno type 1 risk engine, a significantly greater proportion of patients with hepatic steatosis and significant fibrosis (n = 91) had a high 10-year estimated CVD risk compared to those with hepatic steatosis alone (n = 509) or without steatosis (n = 654) (75.8% vs. 23.2% vs. 24.9%, p < 0.001). After adjustment for sex, BMI, diabetes duration, hemoglobin A1c, chronic kidney disease, and lipid-lowering medication use, patients with hepatic steatosis and significant fibrosis had an increased 10-year estimated risk of developing a first fatal or nonfatal CVD event (adjusted-odds ratio 11.4, 95% confidence interval 3.54–36.9) than those without steatosis. We observed almost identical results using the ASCVD risk calculator. CONCLUSIONS: The 10-year estimated CVD risk is remarkably greater in T1DM adults with hepatic steatosis and significant fibrosis than in their counterparts with hepatic steatosis alone or without steatosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01945-x.
format Online
Article
Text
id pubmed-10416459
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104164592023-08-12 Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus Mantovani, Alessandro Morieri, Mario Luca Palmisano, Luisa Masulli, Maria Cossu, Efisio Baroni, Marco Giorgio Bonomo, Katia Cimini, Flavia Agata Cavallo, Gisella Buzzetti, Raffaella Mignogna, Carmen Leonetti, Frida Bacci, Simonetta Trevisan, Roberto Pollis, Riccardo Maria Aldigeri, Raffaella Cas, Alessandra Dei de Kreutzenberg, Saula Vigili Targher, Giovanni Cardiovasc Diabetol Research BACKGROUND: We assessed whether hepatic steatosis with or without significant fibrosis (determined by validated non-invasive biomarkers) is associated with an increased 10-year estimated risk for cardiovascular disease (CVD) in people with type 1 diabetes mellitus (T1DM). METHODS: We conducted a retrospective, multicenter, cross-sectional study involving 1,254 adults with established T1DM without pre-existing CVD. We used the hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting hepatic steatosis (defined as HSI > 36), with or without coexisting significant fibrosis (defined as FIB-4 index ≥ 1.3 or < 1.3). We calculated the Steno type 1 risk engine and the atherosclerotic CVD (ASCVD) risk score to estimate the 10-year risk of developing a first fatal or nonfatal CVD event. RESULTS: Using the Steno type 1 risk engine, a significantly greater proportion of patients with hepatic steatosis and significant fibrosis (n = 91) had a high 10-year estimated CVD risk compared to those with hepatic steatosis alone (n = 509) or without steatosis (n = 654) (75.8% vs. 23.2% vs. 24.9%, p < 0.001). After adjustment for sex, BMI, diabetes duration, hemoglobin A1c, chronic kidney disease, and lipid-lowering medication use, patients with hepatic steatosis and significant fibrosis had an increased 10-year estimated risk of developing a first fatal or nonfatal CVD event (adjusted-odds ratio 11.4, 95% confidence interval 3.54–36.9) than those without steatosis. We observed almost identical results using the ASCVD risk calculator. CONCLUSIONS: The 10-year estimated CVD risk is remarkably greater in T1DM adults with hepatic steatosis and significant fibrosis than in their counterparts with hepatic steatosis alone or without steatosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01945-x. BioMed Central 2023-08-10 /pmc/articles/PMC10416459/ /pubmed/37563618 http://dx.doi.org/10.1186/s12933-023-01945-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mantovani, Alessandro
Morieri, Mario Luca
Palmisano, Luisa
Masulli, Maria
Cossu, Efisio
Baroni, Marco Giorgio
Bonomo, Katia
Cimini, Flavia Agata
Cavallo, Gisella
Buzzetti, Raffaella
Mignogna, Carmen
Leonetti, Frida
Bacci, Simonetta
Trevisan, Roberto
Pollis, Riccardo Maria
Aldigeri, Raffaella
Cas, Alessandra Dei
de Kreutzenberg, Saula Vigili
Targher, Giovanni
Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title_full Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title_fullStr Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title_full_unstemmed Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title_short Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
title_sort hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416459/
https://www.ncbi.nlm.nih.gov/pubmed/37563618
http://dx.doi.org/10.1186/s12933-023-01945-x
work_keys_str_mv AT mantovanialessandro hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT morierimarioluca hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT palmisanoluisa hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT masullimaria hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT cossuefisio hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT baronimarcogiorgio hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT bonomokatia hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT ciminiflaviaagata hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT cavallogisella hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT buzzettiraffaella hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT mignognacarmen hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT leonettifrida hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT baccisimonetta hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT trevisanroberto hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT pollisriccardomaria hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT aldigeriraffaella hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT casalessandradei hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT dekreutzenbergsaulavigili hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus
AT targhergiovanni hepaticsteatosiswithsignificantfibrosisisassociatedwithanincreased10yearestimatedriskofcardiovasculardiseaseinadultswithtype1diabetesmellitus